[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370081-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370081-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","determinants-of-sensitivity-to-her2-targeted-antibody-drug-conjugates-in-urothelial-cancer","Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer","","Determinants of sensitivity to HER2-targeted antibody drug conjugates are investigated in urothelial cancer using large-scale tumor sequencing, patient-derived organoid and xenograft models, and single-cell characterization of genomic and expression heterogeneity. ERBB2 alterations are frequent, and discordance between primary and metastatic sites and between models and originating tumors is observed. Trastuzumab deruxtecan shows significantly greater efficacy than the HER kinase inhibitor neratinib, and ERBB2 co-mutation and amplification correlate with exceptional response in real-world patients. Results support expanding HER2-targeted ADC trials and using functional precision oncology platforms to assess payload sensitivity pre-treatment.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/determinants-of-sensitivity-to-her2-targeted-antibody-drug-conjugates-in-urothelial-cancer/370081/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/determinants-of-sensitivity-to-her2-targeted-antibody-drug-conjugates-in-urothelial-cancer/370081.png","ImageObject",300,407,{"name":42,"@type":43},"anakgang17","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-13","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which ERBB2 alterations were observed in urothelial cancers in this analysis?","Question",{"text":63,"@type":64},"Oncogenic or likely oncogenic ERBB2 alterations were present in 14.5% of urothelial cancers, including ERBB2 mutation, ERBB2 amplification of wildtype ERBB2, and concurrent mutation and amplification.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did trastuzumab deruxtecan perform compared with neratinib in patient-derived models?",{"text":68,"@type":64},"In patient-derived urothelial cancer models, trastuzumab deruxtecan was significantly more effective than the HER kinase inhibitor neratinib.",{"name":70,"@type":61,"acceptedAnswer":71},"What genomic features were linked to exceptional clinical response to trastuzumab deruxtecan?",{"text":72,"@type":64},"In a real-world cohort treated with trastuzumab deruxtecan, ERBB2 co-mutation and amplification were associated with exceptional clinical response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370081,1790822446,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article [https://doi.org/10.1038/s41467-025-67643-2](https://doi.org/10.1038/s41467-025-67643-2)  \nDeterminants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer  \nReceived: 7 May 2025  \n\n| Accepted: 4 December 2025 |\n| --- |\n| |\n| Check for updates |\n\nZiyu Chen1,2,14, Xinran Tang 1,2,14, Jordan E. Eichholz3, Andrew Mcpherson 3,4, Jasmine Thomas5, Karan Nagar5, Naryan Rustgi1, John R. Christin6,  \nFengshen Kuo 1,5, Sizhi Gao1, Hui Jiang 1,5, Jiaqian Luo 1,2,  \nIrina Ostrovnaya 7, Merve Basar8, Eugene Pietzak9, Jonathan A. Coleman9, Michael F. Berger 8,10, Elisa de Stanchina11, Sohrab P. Shah 3,4,  \nNeeman Mohibullah12, David H. Aggen13, Jonathan E. Rosenberg13, SaratChandarlapaty 1, Michael M. Shen6, Hikmat Al-Ahmadie 8, GopaIyer 13, Kwanghee Kim 5 & David B. Solit 1,10,13   \nHER2, encoded by the ERBB2 gene, is a receptor tyrosine kinase frequently activated in human cancers via gene ampliﬁcation, mutation, and/or protein overexpression. In an analysis of 42,415 prospectively analyzed solid tumors, we show that 14.5% of urothelial cancers (n = 295/2,035) have oncogenic or likely oncogenicERBB2 alterations (6.7% ERBB2 mutation, 6.3% ampliﬁcation of wildtype ERBB2, and 1.5% concurrent mutation and ampliﬁcation). Discordance of ERBB2 mutational status between primary and metastatic disease sites is common in patients with urothelial cancer as is discordance ofERBB2 mutational status between patient-derived organoid/xenograft models and the tumors from which they were derived. In patient-derived urothelial cancer models, the HER2-targeted antibody-drug conjugate (ADC) trastuzumab deruxtecan is signiﬁcantly more effective than the HER kinase inhibitor neratinib. In a real-world cohort of patients with urothelial cancer treated with trastuzumab deruxtecan, co-mutation and ampliﬁcation of ERBB2 is associated with exceptional clinical response. Our data support expanded clinical trials of HER2-targeted ADCs for urothelial cancers with low HER2 expression, the clinical testing of HER2 ADCs with alternative cytotoxic payloads, and the development of functional precision oncology platforms capable of assessing payload sensitivity pre-treatment as a guide to individualized therapy selection.  \nTreatment options for patients with bladder and upper tract uro- antibody drug conjugates (ADCs) targeting Nectin-4 and HER21–11. thelial cancer have expanded signiﬁcantly over the past several years. HER2, which is encoded by the ERBB2 gene, is a non-ligand-binding Successful clinical trials have resulted in FDA approval of novel member of the epidermal growth factor family of receptor tyrosine therapies spanning three mechanistically distinct drug classes: kinases12. Despite a high prevalence of HER2 alterations in urothelial immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies), ﬁbro- cancer, clinical trials of older HER2-directed therapies including the blast growth factor receptor 3 (FGFR3) kinase inhibitors, and monoclonal antibody trastuzumab and HER2-selective kinase  \nA full list of afﬁliations appears at the end of the paper. e-mail: [solitd@mskcc.org](solitd@mskcc.org)  \ninhibitors such as neratinib reported disappointing results inpatients with advanced urothelial carcinomas13–16.  \nTrastuzumab deruxtecan (T-DXd) is a second-generation HER2-targeted ADC with a tetrapeptide-based cleavable linker and a topoisomerase I inhibitor payload. T-DXd has demonstrated clinical activity in patients whose tumors were resistant to older HER2-targeted therapies including trastuzumab-resistant HER2-positive breast cancers17,18. Recent clinical results from two T-DXd basket trials (DESTINY-PanTumor01 and DESTINY PanTumor02) have also reported compelling clinical activity pan-cancer, including in patients with HER2 positive and mutant urothelial cancers. Most notably, 39% of patients with HER2 positive urothelial cancer enrolled on the DESTINY PanTumor02 study had a partial response, and 87% stable disease or better19. The","cbCaiidMH7KXPTpc","https://ap.wps.com/l/cbCaiidMH7KXPTpc","pdf",4440476,15,"English","# Study overview\n## HER2/ERBB2 alteration landscape\n## Model-based assessment of ADC sensitivity\n## Clinical response associations\n## Implications for future trials and precision oncology","[{\"question\":\"Which ERBB2 alterations were observed in urothelial cancers in this analysis?\",\"answer\":\"Oncogenic or likely oncogenic ERBB2 alterations were present in 14.5% of urothelial cancers, including ERBB2 mutation, ERBB2 amplification of wildtype ERBB2, and concurrent mutation and amplification.\"},{\"question\":\"How did trastuzumab deruxtecan perform compared with neratinib in patient-derived models?\",\"answer\":\"In patient-derived urothelial cancer models, trastuzumab deruxtecan was significantly more effective than the HER kinase inhibitor neratinib.\"},{\"question\":\"What genomic features were linked to exceptional clinical response to trastuzumab deruxtecan?\",\"answer\":\"In a real-world cohort treated with trastuzumab deruxtecan, ERBB2 co-mutation and amplification were associated with exceptional clinical response.\"}]","Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer | PDF",1790186616,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e441fa4dee6c1ddd82dea928ce3f7b2f.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1667123fe3f1dd5b29abcc421a9d4fd2.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d37f2b598872ab087a14632f95cfcf8d.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69810714b8357fc05b1ca30601bb127a.webp",980,1301]